Logo image of IMMP

IMMUTEP LTD-SP ADR (IMMP) Stock Fundamental Analysis

NASDAQ:IMMP - Nasdaq - US45257L1089 - ADR - Currency: USD

1.88  -0.09 (-4.57%)

After market: 1.89 +0.01 (+0.53%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to IMMP. IMMP was compared to 560 industry peers in the Biotechnology industry. IMMP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. IMMP is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year IMMP has reported negative net income.
IMMP had negative earnings in each of the past 5 years.
IMMP had a negative operating cash flow in each of the past 5 years.
IMMP Yearly Net Income VS EBIT VS OCF VS FCFIMMP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

IMMP has a Return On Assets of -24.06%. This is in the better half of the industry: IMMP outperforms 73.39% of its industry peers.
IMMP has a better Return On Equity (-25.43%) than 80.89% of its industry peers.
Industry RankSector Rank
ROA -24.06%
ROE -25.43%
ROIC N/A
ROA(3y)-26.59%
ROA(5y)-29.03%
ROE(3y)-28.67%
ROE(5y)-33.45%
ROIC(3y)N/A
ROIC(5y)N/A
IMMP Yearly ROA, ROE, ROICIMMP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IMMP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMMP Yearly Profit, Operating, Gross MarginsIMMP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K -40K

More info and screens

6

2. Health

2.1 Basic Checks

IMMP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IMMP has more shares outstanding
The number of shares outstanding for IMMP has been increased compared to 5 years ago.
The debt/assets ratio for IMMP has been reduced compared to a year ago.
IMMP Yearly Shares OutstandingIMMP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
IMMP Yearly Total Debt VS Total AssetsIMMP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

IMMP has an Altman-Z score of 24.25. This indicates that IMMP is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 24.25, IMMP belongs to the top of the industry, outperforming 95.18% of the companies in the same industry.
IMMP has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of IMMP (0.00) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 24.25
ROIC/WACCN/A
WACC9.32%
IMMP Yearly LT Debt VS Equity VS FCFIMMP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 18.86 indicates that IMMP has no problem at all paying its short term obligations.
The Current ratio of IMMP (18.86) is better than 92.86% of its industry peers.
IMMP has a Quick Ratio of 18.86. This indicates that IMMP is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of IMMP (18.86) is better than 92.86% of its industry peers.
Industry RankSector Rank
Current Ratio 18.86
Quick Ratio 18.86
IMMP Yearly Current Assets VS Current LiabilitesIMMP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 14.60% over the past year.
Looking at the last year, IMMP shows a very negative growth in Revenue. The Revenue has decreased by -79.03% in the last year.
The Revenue for IMMP have been decreasing by -54.35% on average. This is quite bad
EPS 1Y (TTM)14.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.87%
Revenue 1Y (TTM)-79.03%
Revenue growth 3Y-27.42%
Revenue growth 5Y-54.35%
Sales Q2Q%8084.48%

3.2 Future

IMMP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 59.58% yearly.
The Revenue is expected to grow by 106.38% on average over the next years. This is a very strong growth
EPS Next Y-18.98%
EPS Next 2Y-10.26%
EPS Next 3Y10.32%
EPS Next 5Y59.58%
Revenue Next Year42.92%
Revenue Next 2Y7.96%
Revenue Next 3Y114.96%
Revenue Next 5Y106.38%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IMMP Yearly Revenue VS EstimatesIMMP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
IMMP Yearly EPS VS EstimatesIMMP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IMMP. In the last year negative earnings were reported.
Also next year IMMP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMMP Price Earnings VS Forward Price EarningsIMMP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMMP Per share dataIMMP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.26%
EPS Next 3Y10.32%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IMMP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMUTEP LTD-SP ADR

NASDAQ:IMMP (5/30/2025, 8:05:00 PM)

After market: 1.89 +0.01 (+0.53%)

1.88

-0.09 (-4.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26 2025-02-26/dmh
Earnings (Next)07-29 2025-07-29/amc
Inst Owners40.78%
Inst Owner Change-13.67%
Ins Owners1.86%
Ins Owner ChangeN/A
Market Cap273.46M
Analysts82.22
Price Target3.1 (64.89%)
Short Float %2.89%
Short Ratio12.93
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)31.95%
PT rev (3m)24.56%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-14.17%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)35.17%
Revenue NY rev (3m)147.83%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7890.83
P/FCF N/A
P/OCF N/A
P/B 2.46
P/tB 2.58
EV/EBITDA N/A
EPS(TTM)-0.21
EYN/A
EPS(NY)-0.29
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0.76
TBVpS0.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.06%
ROE -25.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.59%
ROA(5y)-29.03%
ROE(3y)-28.67%
ROE(5y)-33.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 18.86
Quick Ratio 18.86
Altman-Z 24.25
F-ScoreN/A
WACC9.32%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.87%
EPS Next Y-18.98%
EPS Next 2Y-10.26%
EPS Next 3Y10.32%
EPS Next 5Y59.58%
Revenue 1Y (TTM)-79.03%
Revenue growth 3Y-27.42%
Revenue growth 5Y-54.35%
Sales Q2Q%8084.48%
Revenue Next Year42.92%
Revenue Next 2Y7.96%
Revenue Next 3Y114.96%
Revenue Next 5Y106.38%
EBIT growth 1Y-12.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-23.22%
EBIT Next 3Y4.25%
EBIT Next 5Y15.26%
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A